Payment overview · 2025
General Payments
$749.06
42 reported records · 13 companies
Healthcare provider profile · identity verified
Bhadresh K Patel, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BEVERLY HILLS, FL · NPI 1003913252
Verified facts
What the public records show
CMS Open Payments records show Bhadresh K Patel, M.D. received $749.06 in general payments during 2025 across 42 reported records.
Amgen Inc. accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Nurtec Odt, Ozempic, Prolia, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 278 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $158.06 | 21.1% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $104.56 | 14.0% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $101.82 | 13.6% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $78.76 | 10.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.96 | 8.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.87 | 7.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.91 | 6.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $35.25 | 4.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $30.41 | 4.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.43 | 2.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.68 | 2.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.03 | 2.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.32 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $749.06 | 42 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $106.50 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $106.50 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $104.56 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $78.76 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $51.56 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $51.56 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.91 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.66 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.43 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $35.25 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.98 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $30.41 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 278 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 177 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 129 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 28 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 128 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
95 | 31 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
28 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
278 | 77 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
51 | 25 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
177 | 57 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
14 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
128 | 42 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
327 | 76 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1826 | 619 |
| Amlodipine Besylate | Amlodipine Besylate | 1343 | 443 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1329 | 422 |
| Lisinopril | Lisinopril | 1255 | 440 |
| Losartan Potassium | Losartan Potassium | 1078 | 360 |
| Metformin Hcl | Metformin Hcl | 763 | 274 |
| Omeprazole | Omeprazole | 750 | 259 |
| Gabapentin | Gabapentin | 684 | 233 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 611 | 214 |
| Metoprolol Tartrate | Metoprolol Tartrate | 601 | 216 |
| Simvastatin | Simvastatin | 598 | 207 |
| Hydrochlorothiazide | Hydrochlorothiazide | 552 | 193 |
| Metoprolol Succinate | Metoprolol Succinate | 520 | 173 |
| Pravastatin Sodium | Pravastatin Sodium | 446 | 142 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 419 | 191 |
| Trazodone Hcl | Trazodone Hcl | 408 | 136 |
| Tamsulosin Hcl | Tamsulosin Hcl | 402 | 136 |
| Meloxicam | Meloxicam | 395 | 151 |
| Pantoprazole Sodium | Pantoprazole Sodium | 383 | 148 |
| Furosemide | Furosemide | 377 | 143 |
| Clopidogrel | Clopidogrel Bisulfate | 333 | 113 |
| Eliquis | Apixaban | 327 | 76 |
| Montelukast Sodium | Montelukast Sodium | 311 | 117 |
| Ezetimibe | Ezetimibe | 302 | 115 |
| Sertraline Hcl | Sertraline Hcl | 301 | 98 |
| Carvedilol | Carvedilol | 298 | 97 |
| Escitalopram Oxalate | Escitalopram Oxalate | 286 | 94 |
| Glipizide | Glipizide | 280 | 89 |
| Farxiga | Dapagliflozin Propanediol | 278 | 77 |
| Prednisone | Prednisone | 264 | 192 |
| Fluticasone Propionate | Fluticasone Propionate | 262 | 127 |
| Duloxetine Hcl | Duloxetine Hcl | 245 | 89 |
| Famotidine | Famotidine | 241 | 90 |
| Tizanidine Hcl | Tizanidine Hcl | 228 | 90 |
| Alendronate Sodium | Alendronate Sodium | 220 | 72 |
| Azithromycin | Azithromycin | 210 | 186 |
| Allopurinol | Allopurinol | 207 | 71 |
| Potassium Chloride | Potassium Chloride | 196 | 70 |
| Citalopram Hbr | Citalopram Hydrobromide | 194 | 58 |
| Glimepiride | Glimepiride | 180 | 63 |
| Jardiance | Empagliflozin | 177 | 57 |
| Finasteride | Finasteride | 165 | 51 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 165 | 53 |
| Atenolol | Atenolol | 164 | 59 |
| Xarelto | Rivaroxaban | 146 | 44 |
| Buspirone Hcl | Buspirone Hcl | 145 | 45 |
| Warfarin Sodium | Warfarin Sodium | 143 | 40 |
| Spironolactone | Spironolactone | 141 | 43 |
| Metformin Hcl Er | Metformin Hcl | 137 | 44 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 136 | 54 |
| Fenofibrate | Fenofibrate | 134 | 43 |
| Ozempic | Semaglutide | 129 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 128 | 42 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 127 | 46 |
| Fluoxetine Hcl | Fluoxetine Hcl | 110 | 34 |
| Januvia | Sitagliptin Phosphate | 105 | 31 |
| Baclofen | Baclofen | 101 | 32 |
| Donepezil Hcl | Donepezil Hcl | 101 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 37 |
| Bupropion Xl | Bupropion Hcl | 100 | 34 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 100 | 76 |
| Propranolol Hcl | Propranolol Hcl | 99 | 35 |
| Synthroid | Levothyroxine Sodium | 95 | 31 |
| Oxybutynin Chloride | Oxybutynin Chloride | 93 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 92 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 91 | 77 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 90 | 38 |
| Benazepril Hcl | Benazepril Hcl | 89 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 89 | 34 |
| Clonidine Hcl | Clonidine Hcl | 87 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 85 | 31 |
| Enalapril Maleate | Enalapril Maleate | 84 | 28 |
| Cephalexin | Cephalexin | 82 | 60 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 34 |
| Fenofibrate | Fenofibrate,micronized | 76 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 72 | 63 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 42 |
| Sumatriptan Succinate | Sumatriptan Succinate | 72 | 20 |
| Fluconazole | Fluconazole | 67 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 67 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 65 | 16 |
| Valsartan | Valsartan | 65 | 22 |
| Entresto | Sacubitril/Valsartan | 63 | 19 |
| Ibuprofen | Ibuprofen | 63 | 24 |
| Glipizide Er | Glipizide | 62 | 27 |
| Celecoxib | Celecoxib | 61 | 22 |
| Methylprednisolone | Methylprednisolone | 61 | 51 |
| Amoxicillin | Amoxicillin | 58 | 54 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 48 |
| Mirtazapine | Mirtazapine | 55 | 22 |
| Topiramate | Topiramate | 53 | 19 |
| Lovastatin | Lovastatin | 52 | 23 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 51 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 51 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 51 | 25 |
| Meclizine Hcl | Meclizine Hcl | 49 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 41 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 47 | 18 |
| Spiriva Respimat | Tiotropium Bromide | 47 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 47 | 23 |
| Folic Acid | Folic Acid | 46 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 29 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 44 | 43 |
| Lamotrigine | Lamotrigine | 44 | 16 |
| Chlorthalidone | Chlorthalidone | 43 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 11 |
| Nitroglycerin | Nitroglycerin | 43 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 23 |
| Levetiracetam | Levetiracetam | 42 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 41 | 15 |
| Naproxen | Naproxen | 40 | 17 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 40 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | 12 |
| Divalproex Sodium | Divalproex Sodium | 39 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 39 | 12 |
| Ketoconazole | Ketoconazole | 38 | 12 |
| Memantine Hcl | Memantine Hcl | 38 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 38 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 17 |
| Estradiol | Estradiol | 37 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 37 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | 14 |
| Bumetanide | Bumetanide | 34 | 12 |
| Mupirocin | Mupirocin | 34 | 22 |
| Prazosin Hcl | Prazosin Hcl | 33 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 32 | 11 |
| Digoxin | Digoxin | 32 | 11 |
| Alprazolam | Alprazolam | 31 | 18 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Metronidazole | Metronidazole | 31 | 27 |
| Tramadol Hcl | Tramadol Hcl | 31 | 16 |
| Acyclovir | Acyclovir | 30 | 14 |
| Ondansetron Odt | Ondansetron | 30 | 15 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 29 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 27 |
| Prolia | Denosumab | 28 | 20 |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 14 |
| Clotrimazole | Clotrimazole | 26 | 17 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 13 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | 11 |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 12 |
| Benzonatate | Benzonatate | 24 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Levemir | Insulin Detemir | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | 12 |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | 13 |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | 12 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Colchicine | Colchicine | 19 | 11 |
| Droplet Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Methimazole | Methimazole | 19 | suppressed |
| Nystatin | Nystatin | 19 | 17 |
| Pentoxifylline | Pentoxifylline | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | 13 |
| Telmisartan | Telmisartan | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 15 | suppressed |
| Klor-Con 10 | Potassium Chloride | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Larin Fe | Norethindrone-E.Estradiol-Iron | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Procrit | Epoetin Alfa | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Droplet Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $749.06 · 42 records | Amgen Inc. | AREXVY, CAPVAXIVE, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, KEVEYIS, NURTEC ODT, OTEZLA, Ozempic, PROLIA, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, WATCHMAN FLX, Wegovy, ZAVZPRET, ZORYVE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error